Skip to main content
Figure 3 | BMC Veterinary Research

Figure 3

From: Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

Figure 3

Change in plasma VEGF in toceranib treated dogs. Plasma VEGF concentrations were assessed in dogs prior to toceranib therapy then at 8 hours post dosing on days 1, 7, 14, and 30 of the study. The percent change in plasma VEGF over the 30 day study period was then assessed. Plasma VEGF concentrations increased significantly from baseline over the 30 day study period (p < 0.001). Furthermore, plasma VEGF concentrations appeared to plateau over days 14 to 30. Change in VEGF was associated with Cmax (p < 0.001) but not Tmax (p = 0.74).

Back to article page